Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
As the treatment landscape for acute myeloid leukemia (AML) evolves, evidence-based recommendations are critical to support physicians and other healthcare professionals (HCPs) in their clinical decision-making. The American Society of Hematology (ASH) recently published updated guidelines for treating newly diagnosed AML in older adults, outlining 9 key clinical recommendations.1 These include guidance on selecting between antileukemic treatment and best supportive management; deciding between traditional induction and venetoclax-based regimens; incorporating targeted therapy; the role of stem cell transplantation; and the use of transfusion support.
This article features an interview with Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, who shares valuable insights into various aspects of the guidelines.
The guidelines strongly recommend offering antileukemic therapy (ALT) over supportive care in many older patients. How should clinicians decide who is a suitable candidate for ALT?
How do you decide between intensive induction vs lower-intensity approaches like HMA + venetoclax?
Based on the guidelines, where do targeted agents like FLT3 or IDH inhibitors fit into first-line treatment today?
Once a patient achieves remission, how do you decide on post-remission therapy? When should transplant still be considered in older patients?
What is the role of transfusion support in patients no longer receiving active therapy?
What are the biggest barriers community oncologists may face in implementing these guidelines?
References
- Sekeres MA, Mattison R, Artz A, et al. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2026 Mar;10(6):1897-1928.
The AML Channel on VJHemOnc is supported with funding from BMS and through an educational grant from Jazz Pharmaceuticals.
The supporters have no influence over the production of the content.
